Skip to main content

Table 1 The use of Adefovir for the treatment of HBV graft infection

From: Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues

Author (Reference) No of Patients No patients DNA Pos No patients HBeAg Pos Treatment duration DNA Negative following Treatment HBeAG Seroconversion DNA Change Median Development of Adefovir Resistant Mutants
Echanojauregui [82] 7† 7 5 48 weeks 3 1 -3.19 None reported
Schiff [71] 196* 172 Not reported 56.1 34 Not reported -4.3 None reported
Wai [16] 4* 4 Not reported 24 months (one only received 9 months of therapy) 0 Not reported -2.0 None reported
Neff [19] 9* 9 7 6– 48 months Median 30 months 0* 4 Not reported* None reported
Toniutto [22] 1† 1 0 2 months 1 N/A Initial load not reported but became undetectable No
Beckebaum [83] 1* 1 1 15 months 0 0 2.45 billion to 32, 100 No
Akay [17] 2* 2 Not reported 4 months 2 Not reported 2000 and 17 pg/mL respectively to undetectable No
  1. *-Cases were the development of LAM-resistant mutants while on prophylactic therapy
  2. †- Cases were from the development of de novo LAM-resistant HBV graft infection